Stock ticker :
NYSE
GSK
AS OF
Jan 19, closing price
Price
$45.69
Change
-$1.12 (-2.39%)
Capitalization
$114b
GSK
Stock ticker :
NYSE
20 days until earnings call
Intraday data for
Jan 19, closing price
Price
$45.69
Change
-$1.12 (-2.39%)
Capitalization
$114b

(GSK) Stock Forecast and AI Recommendations

a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor

GlaxoSmithKline plc (GSK) Stock Stock Prediciton and Price Targets

Stock market charts, price targets, analyst ratings and a financial calendar
a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor
A.I.dvisor published
a Summary for GSK with price predictions.
4:00 PM EST Jan 19

Momentum Indicator for GSK turns positive, indicating new upward trend

GSK saw its Momentum Indicator move above the 0 level on January 07, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 41 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 51%.

Stock Forecast, Price, News, Quote

Current price $45.69 crossed the resistance line at $45.84 and is trading between $45.84 resistance and $42.08 resistance lines. Throughout the month of 12/16/21 - 01/19/22, the price experienced a +4% Uptrend. During the week of 01/11/22 - 01/19/22, the stock enjoyed a +1% Uptrend growth.

Technical Analysis (Indicators)
Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for GSK just turned positive on January 11, 2022. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 21 of 53 cases over the following month. The odds of a continued upward trend are 40%.

Following a +3.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 138 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 41%.

The Aroon Indicator entered an Uptrend today. In 90 of 264 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 34%.

Bearish Trend Analysis

The 10-day RSI Indicator for GSK moved out of overbought territory on January 19, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 15 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 38%.

The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 35%.

GSK broke above its upper Bollinger Band on January 18, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.479) is normal, around the industry mean (4.977). P/E Ratio (19.724) is within average values for comparable stocks, (29.340). Projected Growth (PEG Ratio) (3.576) is also within normal values, averaging (2.436). GSK has a moderately high Dividend Yield (0.048) as compared to the industry average of (0.025). P/S Ratio (2.550) is also within normal values, averaging (4.445).

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. GSK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.dvisor published
GlaxoSmithKline plc Earnings Data

GSK is expected to report earnings to fall 37.27% to 62 cents per share on February 09

GlaxoSmithKline plc GSK Stock Earnings Report
Q4'21
Est.
$0.63
Q3'21
Beat
by $0.22
Q2'21
Beat
by $0.24
Q1'21
Beat
by $0.05
Q4'20
Met
by $0.64
The last earnings report on October 27 showed earnings per share of $1.00, beating the estimate of 78 cents. With 8.34M shares outstanding, the current market capitalization sits at 114.03B.
A.I.dvisor found
GlaxoSmithKline plc Dividends
GSK paid dividends on January 13, 2022
GlaxoSmithKline plc GSK Stock Dividends
А dividend of $0.52 per share was paid with a record date of January 13, 2022, and an ex-dividend date of November 18, 2021. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.
A.I.dvisor
published General Information

General Information

Profile
Fundamentals
Details
Industry Pharmaceuticals Major
Address 980 Great West Road, Brentford, Middlesex, TW8 9GS
Phone +44 2080475000
Employees 94066
Web http://www.gsk.com
GSK

Select Stock attributes to show

Capitalization 114B
P/E Ratio 19.72
Risk (Beta) 0.82
Dividend Yield 0.05
Total Cash 3.514B
Total Cash/Share 1.40
Total Debt 25.6B
Total Debt/Equity 231.99
Projected Growth (PEG Ratio) 3.58
Revenue/Share (as % of the share price) 18%
Revenue 33.3B
ROE N/A
Book Value 15.4B
P/B Ratio 5.48
Cash Flow N/A
Earnings 1.724
Average Daily Volume YTD N/A
Common Shares Outstanding - Security Level 1.347B
Current Ratio 0.81
Current Revenue Per Employee 96,496.08
Dividends Per Share - Security 0.38
EBITDA 11B
Float N/A
Float - Current N/A
Gross Income Margin 68.17
Revenue To Assets 5.40
Shares Held By Institutions 17.7B
Shares Outstanding - Current N/A
Total Liabilities 56.9B
Total Volume MTD N/A
Value Over
Gain YTD 3.605
Group Domestic Stock Funds
Category Pharmaceuticals
Total Expense Ratio
Min. Initial Investment 0.00 USD
Fund Existence
Turnover
Front Load
Net Assets 0.00 USD
Manager Tenure
Group Domestic Stock Funds
Category Pharmaceuticals
Capitalization 114.03b USD
P/E Ratio 19.723866
Total Cash 3.51b USD
Projected Growth 3.58
Total Debt 25.61b USD
Revenue 33.33b USD
Risk (Beta) 0.82
Dividend Yield 0.05
Total Cash/Share 1.40
Total Debt/Equity 231.99
Revenue/Share 18.00USD as % of share price
Group Domestic Stock Funds
Category Pharmaceuticals
Net Assets 0.00 USD
Fund Existence
Turnover
Capitalization
Yield
Total Expense Ratio
Investment Style
Risk (Beta)
Group Domestic Stock Funds
Category Pharmaceuticals
Market Capitalization 0.00 USD
Volume 0.00 USD